Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06151197 · ClinicalTrials.gov registry record · Phase 3
Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)
A Phase 3 study of Plantar Fibromatosis and Ledderhose Disease, sponsored by Endo Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 418
- Enrollment target
- 20
- Study locations
NCT06151197 is a Phase 3 study of Plantar Fibromatosis and Ledderhose Disease that is active but no longer recruiting, run by Endo Pharmaceuticals. The registered enrollment target is 418 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT06151197, a Phase 3 study of Plantar Fibromatosis and Ledderhose Disease, is active but no longer recruiting, sponsored by Endo Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 418 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL EN3835
Study Locations (20)
California
- Endo Site 49 - Castro Valley
- Endo Site 39 - Cerritos
- Endo Site 31 - Corona
- Endo Clinical Site 2 - Encinitas
- Endo Site 8 - Fresno
- Endo Site 28 - Lancaster
- Endo Site 9 - Los Angeles
- Endo Site 53 - Los Angeles
- Endo Site 50 - San Francisco
- Endo Site 29 - Sherman Oaks
- Endo Site 30 - Tarzana
- Endo Site 61 - Torrance
Arizona
- Endo Site 42 - Mesa
- Endo Site 64 - Scottsdale
- Endo Site 11 - Tucson
Colorado
- Endo Site 47 - Johnstown
- Endo Site 65 - Parker
- Endo Site 17 - Westminster
Florida
- Endo Site 22 - Hialeah
- Endo Site 59 - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 2023-11-28 |
| Est. Completion | 2026-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06151197
The ClinicalTrials.gov registry entry for NCT06151197 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 418 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Plantar Fibromatosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06151197 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT06151197 about?
NCT06151197 is a clinical study titled "Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)". This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).
What is the current status of trial NCT06151197?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 418 participants. The study started on 2023-11-28. Estimated completion is 2026-03.
What conditions does trial NCT06151197 study?
This clinical trial studies the following conditions: Plantar Fibromatosis, Ledderhose Disease.
What interventions are being tested in trial NCT06151197?
The interventions under investigation include: Placebo (OTHER), EN3835 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06151197?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06151197 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plantar Fibromatosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.